Page last updated: 2024-08-26

fotemustine and Bone Marrow Diseases

fotemustine has been researched along with Bone Marrow Diseases in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bensadoun, JR; Bonneterre, J; Bourdin, S; Clavel, M; Cupissol, D; de Gislain, C; Delaunay, MM; Guillot, B; Hauschild, A; Lesimple, T; Mohr, P; Mornex, F; Mousseau, M; Nguyen, BB; Thomas, L; Tilgen, W; Ulrich, J1
Antoine, E; Auclerc, G; Benhammouda, A; Bizzari, JP; Borel, C; Paraiso, D; Petit, T; Rixe, O; Soubrane, C; Weil, M1

Trials

2 trial(s) available for fotemustine and Bone Marrow Diseases

ArticleYear
[Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2003, Volume: 7, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Diseases; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Disease Progression; Female; Humans; Life Tables; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Survival Analysis; Treatment Outcome

2003
Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients.
    Melanoma research, 1995, Volume: 5, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Risk; Salvage Therapy; Survival Rate; Treatment Outcome; Vindesine

1995